$AUPH paper published on Gazyva P2 trial, takes twice as long (2 yrs) to achieve similar effect as VOC with , at 1 yr results were not statistically significant, stated cumulative steroid dose probably at least 2x as high as VOC. If approved and launched in 2026+, Gazyva could replace Benlysta as a better B-cell IV therapy in LN: ard.bmj.com/content/annrheu...
@biolurker1 no doubt it will, but Benlysta is always going to be around as a second line therapy, which is still a good thing for people with LN.